Publication:
Therapeutic vaccine trails in Thailand.

dc.contributor.authorVina Churdbooncharten_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-07-24T03:42:43Z
dc.date.available2018-07-24T03:42:43Z
dc.date.issued2004-09-01en_US
dc.description.abstractAn effective therapeutic HIV vaccine will not only benefit the HIV-infected person but will also provide invaluable information on effective immune response in designing or selecting a preventive vaccine. A phase II double-blind controlled clinical trial using HIV-1 immunogen (Remune) was undertaken in Thailand in 1995 in conjunction with phase III approval in the USA. In most instances, immune response to the virus was induced. The results from this study led to the extension of further trials over the following 4 years. At present, the Thai Food and Drug Administration (FDA) is in the process of reviewing the files on all information to assess the effectiveness of this therapeutic vaccine as well as reviewing the proposal to conduct a phase III trial to further confirm previous efficacy results from the phase II trials.en_US
dc.identifier.citationJournal of HIV therapy. Vol.9, No.3 (2004), 57-59en_US
dc.identifier.issn14620308en_US
dc.identifier.other2-s2.0-16544369822en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/21357
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=16544369822&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.titleTherapeutic vaccine trails in Thailand.en_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=16544369822&origin=inwarden_US

Files

Collections